- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02432651
Xanthohumol and Prevention of DNA Damage
Prevention of Oxidative DNA Damage by Xanthohumol
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this research study is to learn if and in what amount a compound from hops, called xanthohumol (ZAN-tho-HUE-mol), prevents damage to DNA and oxidative stress. The human body is constantly exposed to oxidative stress from environmental compounds (e.g. air pollution) which may cause damage to DNA. The human body can repair some DNA damage, but too much DNA damage is harmful and may lead to cancer. Research done at OSU and around the world has shown that xanthohumol can stop or slow processes that lead to cancer.
Participants will consume a non-alcoholic beverage containing xanthohumol with breakfast, lunch and dinner for 3 weeks. Then they will go through a washout period of 3 weeks. And then they will consume the same beverage without the xanthohumol compound (placebo) for another 3 weeks. Participants will be randomly assigned into groups and will vary whether they will consume the xanthohumol product during the first or second 3-week period. Xanthohumol doses will be 0, 6, 12 or 24 mg/day.
The study includes donation of blood and urine samples and one-month food frequency questionnaires.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Oregon
-
Corvallis, Oregon, United States, 97331
- Oregon State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-smokers or no other tobacco use in the past 3 months.
- Willing to stop taking regular supplements including anti-oxidants for 2 weeks prior to study entry through conclusion of study.
- Willing to stop consumption of high levels of flavonoids and xanthohumol in the normal diet (onions, teas including green/black tea and microbrew beers) for 2 weeks prior to study entry through conclusion of study.
- Must be able to give written informed consent.
- Blood screen tests (Comprehensive metabolic profile [CMP] and lipid profile) within normal limits.
Exclusion Criteria:
- Body Mass Index (BMI) less than 18.5 (underweight) or greater than 30 (obese)
- Have a significant acute or chronic coexisting illness such as cardiovascular disease, chronic kidney or liver disease, gastrointestinal disorder, endocrinological disorder, immunological disorder, metabolic disease, cancer, history of chemotherapy, celiac disease or gluten/wheat intolerance*, diabetes, thyroid problems, or any condition which contraindicates, in the investigators judgement, entry into the study.
- Currently taking prescription drugs except oral contraceptives.
- Consumption of more than the recommended alcohol guidelines i.e. >2 drinks/day.
- Consumption of high levels of flavonoids and xanthohumol in the normal diet (onions, teas including green/black tea and microbrew beers).
- Pregnancy (as confirmed by urine pregnancy test), breastfeeding, or planning to become pregnant before completing the study.
- Undergoing UV therapy (e.g. treatment for skin conditions such as psoriasis), using UV tanning beds, or unprotected sun exposure greater than 1 hour per day.
- Engaging in vigorous exercise more than 6 hours per week.
- Participation in another dietary study in the past 3 months.
- Had surgery in the last 3 months.
- Post-menopausal status
(*Note: Beverage is formulated with a barley extract. Barley contains gluten.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 6 mg xanthohumol per day vs. placebo
All participants take 6 mg xanthohumol daily and placebo in a crossover design with a washout period.
|
Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
|
Other: 12 mg xanthohumol per day vs. placebo
All participants take 12 mg xanthohumol daily and placebo in a crossover design with a washout period.
|
Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
|
Other: 24 mg xanthohumol per day vs. placebo
All participants take 24 mg xanthohumol daily and placebo in a crossover design with a washout period.
|
Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the change in markers of DNA damage and oxidative stress during XN treatment vs. the change during placebo
Time Frame: Prior to first dose on day 1 to day 63.
|
Plasma and urine levels of 8-oxo-dG will be measured at the beginning and end of each 3-week cycle.
DNA strand breaks in blood cells and plasma levels of reduced and oxidized glutathione will be measured at the beginning and end of each 3-week cycle.
Between the two cycles, there will be a 3-week washout.
One cycle is XN treatment, and one cycle is the placebo.
|
Prior to first dose on day 1 to day 63.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the change in metabolic profile during XN treatment vs. the change during placebo
Time Frame: Prior to first dose on day 1 to day 63.
|
Metabolome measurements in plasma at beginning and end of first 3-week cycle with 3-week.
Between the two cycles, there will be a 3-week washout period between cycles.
One cycle is XN treatment, and one cycle is the placebo.
|
Prior to first dose on day 1 to day 63.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jan Frederik Stevens, PhD, Oregon State University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LPI-6119
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oxidative Stress
-
FertilysRecruiting
-
Idaho State UniversityCompletedOxidative StressUnited States
-
Unidad de Investigacion Medica en Enfermedades...Completed
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...Completed
-
Complife Italia SrlMacrofarm Srl; Icim International SrlCompleted
-
Indonesia UniversityIndonesia-MoHCompleted
-
Assiut UniversityCompleted
-
Universidad Católica San Antonio de MurciaCompleted
-
Nationwide Children's HospitalWithdrawn
-
University of Colorado, DenverCompleted
Clinical Trials on 6 mg xanthohumol per day
-
TCM Biotech International Corp.Recruiting
-
Joben Bio-Medical Co., Ltd.Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaboratorsUnknownRadiodermatitisTaiwan
-
Federal Budgetary Research Institution State Research...CompletedSmallpox | Monkeypox | Cowpox | Vaccinia Virus InfectionRussian Federation
-
University of SydneyInje University; Korea Agro-Fisheries Trade Corporation, Seoul, Korea; Ministry...Unknown
-
Dr. Frank BehrensBionorica SEActive, not recruitingDrug-induced Liver InjuryGermany
-
Ayesha De CostaBoston Children's Hospital; Muhimbili University of Health and Allied Sciences and other collaboratorsCompleted
-
Tri-Service General HospitalCompleted
-
Otsuka Pharmaceutical Co., Ltd.TerminatedAgitation Associated With Dementia of the Alzheimer's TypeJapan
-
Forest LaboratoriesCompletedGeneralized Anxiety DisorderUnited States
-
ValbiotisBiofortis Mérieux NutriSciencesCompletedDiabetes type2 | Prediabetic State | DysglycemiaItaly, France, Germany, Poland, Romania, Bulgaria, Hungary